Life Sciences Infrastructure
A technology-first approach to drug development infrastructure. Our TEAMS framework delivers treatments 20% faster and 20% cheaper — ending the era of $2B, 12-year development cycles.
How We Got Here
Monument Square Group's focus has always been to find overlooked opportunities. We deployed the same lens when we were approached by life science experts to reimagine how life sciences is done. But what we discovered went far beyond physical infrastructure — it demanded a complete overhaul of people's perceptions and decades-old operations and processes. What we discovered changes everything.
Our roots
Our Strength: Pattern recognition.
Great things happen when we synthesize insights from disparate domains like change management, financial analysis, commercial real estate strategy, and operational systems and connect those perspectives with People, Ideas, and Capital.
The discovery
A culture of continuous learning, curiosity, and a willingness to take on hard projects opened the door to looking inside life sciences.
What we found wasn't just a story about equipment and physical infrastructure. The real story was the systemic problems hindering an essential industry. We studied the reasons for these massive inefficiencies and their impacts on people, processes, and the final product.
Now
Reimagining how life science is done
Our research showed that fundamental changes were needed — not in the science, but in the infrastructure around it. Rebuilding the infrastructure around technology instead of equipment means we can get treatments to patients everywhere faster and for less money. This is our mission and what we work on everyday.
The conviction
The major bottleneck in life sciences isn't the science. It's the infrastructure built to support it. No one has reimagined that infrastructure like we have.
Doing what others won't or can't do is what MSG has done from the beginning. Now we're applying our approach to the largest inefficiency affecting lives everywhere.
The Problem
Traditional drug development is locked in an equipment-centric model built decades ago. The infrastructure hasn't evolved. The only thing that has changed is the cost to bring treatments to patients has increased over the past 20 years.
The Traditional Model
Equipment-centric: Static, immobile equipment that is walled off from scientists
Siloed expertise: Researchers isolated across separate facilities
Linear processes: Sequential steps where each waits on the last
Capital inefficiency: Overhead and administrative costs consume disproportionate amounts of funding meant for research
The TEAMS Approach
Technology: Software-defined capabilities remove siloed data that hinders knowledge transfer and discourages collaboration
Efficiency: Scientists spend more time on the science and the mission
Automation: Amplifies scientists' impact at a time when they're being asked to do more with less
Modularity: Spaces that change with scientists' needs and reconfigure seamlessly
Scalability: The technology infrastructure scales as scientists' needs scale removing barriers to growth
20%
Faster development
timelines
20%
Lower capital
requirements
$1.1T
U.S. pharma market
by 2034
The Opportunity
We sit at the intersection of market forces that have never aligned before — and the window to define this category is open now.
The life sciences industry has never seen a period like what we're in now - funding challenges, increased competition, uncertain regulation, technological upheaval, and the demand to produce treatments faster than ever.
A fresh, different approach is needed. This is where we excel. We analyze, synthesize, and execute our technology, infrastructure, capital, and life sciences expertise in a way no one else does.
We're not betting on a single new treatment. We're building the infrastructure layer — a whole new platform — that makes every drug development faster and cheaper.
Pharmaceutical companies currently spend $2B per approved drug on average. Even modest penetration of that inefficiency represents a generational opportunity.
Partner With Us
We're passionate about our mission and we like to talk with other passionate people. Reach out to us if you're an investor, a biotech innovator, or a development partner who shares our passion.
Or reach us directly at info@monumentsquaregroup.com